Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization

Completed 24 enrolled Walter Reed Army Medical Center Massachusetts Eye and Ear Infirmary · collab

NaSingle-groupOpen-labelTreatment

Summary

Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.

Timeline

Start: 2007-08
Primary completion: 2011-01
Completion: 2011-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	10 mg/ml	Topical

Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization

Summary

Timeline

Drugs

Indications